Distinct Modes of Balancing Glomerular Cell Proteostasis in Mucolipidosis Type II and III Prevent Proteinuria
Authors: Wiebke Sachs, Marlies Sachs, Elke Krüger, Stephanie Zielinski, Oliver Kretz, Tobias B. Huber, Anke Baranowsky, Lena Marie Westermann, Renata Voltolini Velho, Nataniel Floriano Ludwig, Timur Alexander Yorgan, Giorgia Di Lorenzo, Katrin Kollmann, Thomas Braulke, Ida Vanessa Schwartz, Thorsten Schinke, Tatyana Danyukova, Sandra Pohl, Catherine Meyer-Schwesinger
Journal: Journal of the American Society of Nephrology (2020)

Significance Statement Patients with the severe lysosomal storage disorder mucolipidosis II (MLII) have mild microalbuminuria, among other symptoms, but patients with the milder MLIII do not have proteinuria. Both conditions result from mutations in the same gene. Mouse models of each disorder reveal that distinct mechanisms compensate for the disruption in protein synthesis balance in glomeruli. Both MLII and MLIII downregulate the protein complex mTORC1 (mammalian target of rapamycin complex 1) signaling to dampen protein synthesis, but MLII also increases the integrated stress response and MLIII activates the proteasome system. Background The mechanisms balancing proteostasis in glomerular cells are unknown. Mucolipidosis (ML) II and III are rare lysosomal storage disorders associated with mutations of the Golgi-resident GlcNAc-1-phosphotransferase, which generates mannose 6-phosphate residues on lysosomal enzymes. Without this modification, lysosomal enzymes are missorted to the extracellular space, which results in lysosomal dysfunction of many cell types. Patients with MLII present with severe skeletal abnormalities, multisystemic symptoms, and early death; the clinical course in MLIII is less progressive. Despite dysfunction of a major degradative pathway, renal and glomerular involvement is rarely reported, suggesting organ-specific compensatory mechanisms. Methods MLII mice were generated and compared with an established MLIII model to investigate the balance of protein synthesis and degradation, which reflects glomerular integrity. Proteinuria was assessed in patients. High-resolution confocal microscopy and functional assays identified proteins to deduce compensatory modes of balancing proteostasis. Results Patients with MLII but not MLIII exhibited microalbuminuria. MLII mice showed lysosomal enzyme missorting and several skeletal alterations, indicating that they are a useful model. In glomeruli, both MLII and MLIII mice exhibited reduced levels of lysosomal enzymes and enlarged lysosomes with abnormal storage material. Nevertheless, neither model had detectable morphologic or functional glomerular alterations. The models rebalance proteostasis in two ways: MLII mice downregulate protein translation and increase the integrated stress response, whereas MLIII mice upregulate the proteasome system in their glomeruli. Both MLII and MLIII downregulate the protein complex mTORC1 (mammalian target of rapamycin complex 1) signaling, which decreases protein synthesis. Conclusions Severe lysosomal dysfunction leads to microalbuminuria in some patients with mucolipidosis. Mouse models indicate distinct compensatory pathways that balance proteostasis in MLII and MLIII.